Shanghai SIMR Biotechnology Co.,Ltd

中文 | EN

中文 EN

Expanded Access Policy Press Releases

Home > MEDIA

MEDIA

Expanded Access Policy

23 2023-02

SIMR Announces Achievement of SR1375 Milestone for Chinese P

On 26th Dec 2022, Shanghai SIMR Biotechnology Co., Ltd. (hereinafter “SIMR”) announced that SR1375, a drug candidate for the treatment of diabetic retinopathy with a new mechanism of action, that is i...
23 2023-02

SIMR Announces Postive Results for SR419 in Dose Escalation

On October 15, 2021, Shanghai SIMR Biotechnology Co., Ltd. (hereinafter “SIMR” or “Company”) announced that the single dose escalation study for SR419 has been successfully completed. This Phase I bri...
03 2023-01

Milestone - SR1375'S Phase II Clinical Trial Approved by th

On December 13, 2022，Shanghai SIMR Biotechnology Co., Ltd announced that, the candidate drug SR1375 with a new mechanism of action for the treatment of acute inflammation solely developed by the compa...
12 2022-11

Shanghai SIMR Biotech received 150 million Chinese Yuan C1 r

On November 8, 2022, Shanghai SIMR Biotech (here in after referred to as "SIMR Bio " or the "Company") announced that it has obtained a C1 round of financing of 150 million Chinese...
12 2022-11

Shanghai SIMR Biotech received 150 million Chinese Yuan C1 r

On November 8, 2022, Shanghai SIMR Biotech (here in after referred to as "SIMR Bio " or the "Company") announced that it has obtained a C1 round of financing of 150 million Chinese...
13 2022-05

Expanded Access Policy for SR419

At SIMR we aspire to discover and develop differentiated therapeutics for the treatment of peripheral neuropathic pain. SIMR’s lead product, SR419, is a candidate drug with novel mechanism of action f...

Home Previous 1 2 3 Next Last

Previous Next Road 3 page 17 strip